A recent study, published in Nature Medicine, showed that Tirzepatide helped people lose more than 60 pounds, or at least one-quarter of their body weight, when used along with lifestyle changes.
While Semaglutide is quite effective for weight loss, it’s not intended for everyone. In fact, Semaglutide as Ozempic® is meant to be prescribed for diabetes, but when sold under the name Wegovy® it is FDA-approved to treat overweight and obesity. A similar drug (Tirzepatide) is sold as Mounjaro® for diabetes and won FDA approval in November 2023 to treat obesity under the name Zepbound® .
Tirzepatide has also been shown to reduce BP in clinical studies. The patients treated with tirzepatide showed significantly lowered systolic and diastolic BP compared with patients in the control group, regardless of whether tirzepatide was used as a monotherapy or add-on therapy.
Low-grade inflammation has been identified as a significant risk factor for cardiovascular diseases. Tirzepatide treatment has been shown to have favorable effects on inflammatory markers in clinical trials. In a 26-week phase 2 study involving patients with obesity and T2DM.
From the New England Journal of Medicine Published July of 2022
From the National Library of Medicine Published October of 2023